Medicare PBM Accountability Act

Bill 118 s 2254, also known as the Medicare PBM Accountability Act, aims to increase transparency and accountability in the pharmaceutical industry, specifically focusing on Pharmacy Benefit Managers (PBMs) within the Medicare program. PBMs are third-party administrators that manage prescription drug benefits for health insurance plans.

The main provisions of this bill include requiring PBMs to disclose information about their pricing practices, rebates, and discounts they negotiate with drug manufacturers. This information would be made available to the Centers for Medicare and Medicaid Services (CMS) and the public, in order to ensure that Medicare beneficiaries are receiving the best possible prices for their prescription drugs.

Additionally, the bill seeks to address potential conflicts of interest within the PBM industry by prohibiting PBMs from owning or having a financial interest in pharmacies. This is intended to prevent PBMs from steering patients towards pharmacies that they have a financial stake in, rather than the most cost-effective option for the patient. Furthermore, the bill includes provisions to improve oversight of PBMs by requiring them to report any potential fraud or abuse to CMS, as well as establishing penalties for non-compliance with these reporting requirements. Overall, the Medicare PBM Accountability Act aims to increase transparency and accountability within the pharmaceutical industry, particularly in relation to PBMs operating within the Medicare program. By requiring PBMs to disclose pricing information and prohibiting conflicts of interest, this bill seeks to ensure that Medicare beneficiaries are receiving the best possible prices for their prescription drugs.